Duration of benefit following completion of pulmonary rehabilitation in interstitial lung disease-An observational study

QJM: An International Journal of Medicine

Volumn 110, Issue 1, 2017, Pages 17-22

  Sharp, C ^a,b   McCabe, M ^c   Hussain, M J ^a   Dodd, J W ^b   Lamb, H ^a   Adamali, H ^a   Millar, A B ^b   Smith, D ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

AGED; ARTICLE; CHRONIC RESPIRATORY QUESTIONNAIRE; EXERCISE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HOME CARE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PULMONARY REHABILITATION; RETROSPECTIVE STUDY; TREATMENT DURATION; EXERCISE TOLERANCE; KINESIOTHERAPY; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY; WALKING;

AGED; AGED, 80 AND OVER; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HUMANS; LINEAR MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WALKING;

EID: 85014106497     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcw105     Document Type: Article

References (34)

1. Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005; 3:61.
2. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116:1175-82.
3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-82.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-92.
5. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatmentrefractory interstitial lung disease. Respirology 2014; 19:353-9.
6. Sharp C, Dodds N, Mayers L, Millar AB, Gunawardena H, Adamali H. The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. QJM 2015; 108:683-8.
7. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl. 5):v1-58.
8. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg163 (6 March 2015, date last accessed).
9. Idiopathic Pulmonary Fibrosis in Adults: Quality Standard 79. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/qs79 (6 March 2015, date last accessed).
10. McCarthyB, CaseyD, DevaneD, MurphyK, Murphy E, LacasseY. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 2:CD003793.
11. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax 2013; 68(Suppl. 2):ii1-30.
12. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10:CD006322.
13. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1428-46.
14. Johnson-Warrington V, Williams J, Bankart J, Steiner M, Morgan M, Singh S. Pulmonary rehabilitation and interstitial lung disease: aiding the referral decision. J Cardiopulm Rehabil Prev 2013; 33:189-95.
15. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63:549-54.
16. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-8.
17. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996; 49:1215-9.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70.
19. Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, et al. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis 2015; 12:93-101.
20. Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, et al. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax 2008; 63:115-21.
21. Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 2014; 108:203-10.
22. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015; 193:345-54.
23. Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012; 106:429-35.
24. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81:196-205.
25. Ochmann U, Kotschy-Lang N, Raab W, Kellberger J, Nowak D, Jorres RA. Long-term efficacy of pulmonary rehabilitation in patients with occupational respiratory diseases. Respiration 2012; 84:396-405.
26. Dalichau S, Demedts A, Sande A, Moller T. Improvement of lasting effects in outpatient pulmonary rehabilitation with special regard to exercise therapy and sports. Rehabilitation 2010; 49:30-7.
27. Dalichau S, Demedts A, Sande A, Moller T. Short-and long-term effects of the outpatient medical rehabilitation for patients with asbestosis. Pneumologie 2010; 64:163-70.
28. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135:442-7.
29. Dowman L, McDonald CF, Hill C, Lee A, Barker J, Boote C, et al. Effect of disease aetiology on response to exercise training in patients with interstitial lung disease. Am Thorac Soc Int Conf 2015; A2460-A.
30. Mendoza L, Gogali A, Shrikrishna D, Cavada G, Kemp SV, Natanek SA, et al. Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology 2014; 19:138-43.
31. Watanabe F, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Respir Med 2013; 107:622-8.
32. Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. Respir Care 2014; 59:1108-15.
33. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188:e13-64.
34. Lost in the System: IPF, the patient experience in England London: British Lung Foundation. http://www.blf.org.uk/Page/IPF-report-Lost-in-the-System (6 March 2015, date last accessed).